

**PHYSICIAN ASSISTANT POLICY COMMITTEE MINUTES  
December 10, 2013**

The meeting was called to order at approximately 1:35 p.m. on Tuesday, December 10, 2013.

Committee members present: Melissa Bowlby, PA-C; Margaret Huwer, Pharm.D.; Anita Steinbergh, D.O.; James Fry, PA-C; and Eric Luckage.

Staff members present: Sallie Debolt, and Cathy Hacker

Guests: Beth Adamson, Executive Director, OAPA

**I. Review of the October 8, 2013 minutes.**

Due to the lack of quorum for the start of the regular meeting Ms. Bowlby began the meeting by discussing the new FDA approved drug from facts and comparison from July 2012 through December 2012. Once the drug discussion was over the committee had not returned to the approval of the minutes. The October 2013 minutes of the P APC will be returned to the next available P APC meeting for approval.

**II. Formulary Review**

The committee considered the following medications and made these changes to the formulary:

**Ximino: already in the CTP may prescribe category no change**

**Rayos: tabled to gather further information**

**Vascepa: already in the CTP may prescribe category no change**

**Tudorza Pressair: already in the CTP may prescribe category no change**

**Prepopik already in the CTP may prescribe category no change**

**Zaltrap: already in the CTP may not prescribe category no change**

**Auvi-Q already in the CTP may prescribe category no change**

**Marqibo Kit: already in the CTP may not prescribe category no change**

**Linzess: already in the CTP may prescribe category no change**

**Stribild: added to the formulary as PI**

**Revatio: already in the PI category no change**

**Xtandi: already in the CTP may not prescribe category no change**

**Afinitor Disperz: already in the CTP may not prescribe category no change**

**Quillivant XR: already in the PI category no change**

**Lotemax: already in the PI category no change**

**Aubagio: already in the CTP may not prescribe category no change**

**Stivarga: already in the CTP may not prescribe category no change**

**Bosulif: already in the CTP may not prescribe category no change**

**Jetrea: added to the CTP may not prescribe category**

**Cystaran: added to the CTP may not prescribe category**

**Bethkis: added to the PI category**

**Fycompa: tabled to gather further information**

**Ilevro: already in the PI category no change**

**Synribo: already in the CTP may prescribe category no change**

**Minivelle: already in the CTP may prescribe category no change**

**Nucynta: already in the CTP may prescribe category no change**

**Xeljanz: already in the PI category no change**

**Cometriq: already in the CTP may not prescribe category no change**

**Signifor: already in the CTP may not prescribe category no change**  
**Eliquis: already in the PI category no change**  
**Fulyzaq: tabled to gather further information**  
**Gattex Kit: added to CTP may not category**  
**Iclusig: already in the CTP may not prescribe category no change**  
**Lupaneta Pack: added to formulary as PI**  
**Juxtapid: added to the PI category**  
**Adrenalin: already in the CTP may prescribe category no change**  
**Sirturo: added to the PI category**

Dr. Steinbergh moved to approve the formulary as amended. Mr. Fry seconded the motion. All members voted aye. The motion carried.

Mr. Luckage questioned why this committee is reviewing these medications that are already on the formulary and there is no need for discussion or change.

Ms. Hacker informed the committee that in the past one of the Pharmacist members used to review these medications and only submitted the ones that were not already on the formulary and needed to be discussed. Due to the change in committee members the way we are reviewing the formulary has changed. The committee has requested that in the future one of the Pharmacist members review the medications that have been FDA approved and only present those that are truly new to the formulary for discussion.

The committee then moved the discussion to the request from Ms. Denise Close that is requesting that the following medications be added to the formulary as physician initiated instead of the CTP may not category that they are currently in: Levulan Kerastick, Accutane, Clavaris, Sotret, and Soriatane.

The committee discussed the dangers associated with the use of these medications and felt that they should stay in the CTP may not prescribe category, due to the potential for patient harm if not used properly.

Dr. Steinbergh moved to deny the request to move Accutane, Clavaris, Sotret, and Soriatane from the CTP may not category to the physician initiated category of the formulary. Mr. Fry seconded the motion. All members voted aye. The motion carried.

Dr. Steinbergh moved to deny the request to move Levulan Kerastick from the CTP may not category to the physician initiated category. Mr. Luckage seconded the motion. All members voted aye. The motion carried.

The committee then discussed the request from Merck & Co that is requesting that the formulary be changed to reflect that the Nuvaring be added to the metabolic agents section under the sex hormones/contraceptive hormones and removed from the renal and genitourinary agents category. Ms. Huwer noted that the formulary already has a category that covers these types of birth control methods however, she wants to look at the nurse practitioner formulary and see where Nuvaring falls in that formulary.

Ms. Huwer moved to table this request until she could gather further information. Dr. Steinbergh seconded the motion. All members voted aye. The motion carried.

The committee reviewed the request from Dr. Mostow that is requesting that Mirvaso be added to the formulary as CTP may prescribe so long as the supervising physician is a Board Certified Dermatologist.

The committee did not feel that they had enough experience or information regarding this medication and recommended that it be referred to the PA Committee of the Board for Dr. Bechtel's expertise. No vote was taken.

The committee reviewed the request from Dr. Mostow that is requesting that Absorica, Claravis, Sotret and Zenitane be changed on the formulary from CTP may not prescribe to the physician initiated category provided that the supervising physician is a Board Certified Dermatologist. The committee had taken a vote on these medications earlier in the meeting denying the request for the change in the formulary for these medications due to the potential for patient harm if not used properly.

The request from Dr. Mostow requesting that Aldara and Zyclara be moved from the CTP may not prescribe category to the CTP may prescribe category provided that the supervising physician is a Board Certified Dermatologist was referred to the PA Committee of the Board for Dr. Bechtel's expertise in the use of this medication. No vote was taken.

### ***III. Review Special Services applications***

The committee discussed the application from Cardinal Orthopaedic Institute that is requesting approval of: carpal tunnel injection, ligament/tendon sheath/trigger digit injection, glenohumeral joint injections, elbow injection, and trigger point injections.

The committee requested that a letter be sent to this group asking them to amend their applications to reflect that the physician will make the decision for the initial injection and that the PA(s) would have 2 years of orthopaedic experience.

Dr. Steinbergh moved to approve these applications when amended. Mr. Fry seconded the motion all members voted aye. The motion carried.

### ***IV. New Business matters***

Ms. Bowlby inquired about the progress of the tabled model supervisory plan for orthopaedics and asked if it could be reviewed at the next meeting. Ms. Debolt indicated that she had recently gained an assistant which would allow Ms. Debolt more time to review the model supervisory plan for orthopedists.

The Physician Assistant Policy Committee meeting was adjourned by Ms. Bowlby at approximately 3:25 p.m. on Tuesday, December 10, 2013.

I hereby attest that these are the true and accurate minutes of the Physician Assistant Policy Committee of the State Medical Board of Ohio, meeting on December 10, 2013.

---

Melissa Bowlby, PA-C  
Chair, PAPC

Copies of documents and/or materials referenced in the minutes of the Physician Assistant Policy Committee meeting are available at the Board offices.